Alternate site health provider Option Care Health (NASDAQ:OPCH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 16.3% year on year to $1.33 billion. The company’s full-year revenue guidance of $5.5 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.40 per share was 19% above analysts’ consensus estimates.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.
U.S.-listed shares of BP fell in premarket trading Tuesday after the British energy giant posted lower-than-estimated first-quarter earnings and reduced its stock buyback as increased economic uncertainty weighs on oil prices.
Mark Zuckerberg, who notoriously dropped out of Harvard, said college pay prove more beneficial from a social standpoint as opposed to career.
Casual restaurant chain Brinker International (NYSE:EAT) announced better-than-expected revenue in Q1 CY2025, with sales up 27.2% year on year to $1.43 billion. The company’s full-year revenue guidance of $5.34 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.66 per share was 3.6% above analysts’ consensus estimates.
Enterprise data capture company Zebra Technologies (NASDAQ:ZBRA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.3% year on year to $1.31 billion. The company expects next quarter’s revenue to be around $1.28 billion, close to analysts’ estimates. Its non-GAAP profit of $4.02 per share was 11.1% above analysts’ consensus estimates.
The VIX fear index has declined 22% in the last five days — suggesting that investors are expecting less drama in front of them than they have behind.
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.
Industrial conglomerate Honeywell (NASDAQ:HON) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.9% year on year to $9.82 billion. On the other hand, the company’s full-year revenue guidance of $40.05 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $2.51 per share was 13.6% above analysts’ consensus estimates.